Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31489 | 0.84 | RAB9A (0.72) | KDM4ENPC1LMNAMAPTRAB9A | |
| SCHEMBL29989068 | 0.84 | RAB9A (0.72) | KDM4ENPC1LMNAMAPTRAB9A | |
| SCHEMBL5318233 | 0.82 | KDM4E (0.63) | KDM4ENPC1LMNAMAPTRAB9A | |
| SCHEMBL19029395 | 0.82 | KDM4E (0.56) | KDM4ENPC1LMNAMAPTRAB9A | |
| SCHEMBL11947887 | 0.82 | KDM4E (0.56) | KDM4ENPC1LMNAMAPTRAB9A | |
| SCHEMBL30897550 | 0.82 | KDM4E (0.56) | KDM4ENPC1LMNAMAPTRAB9A | |
| SCHEMBL28439988 | 0.82 | KDM4E (0.56) | KDM4ENPC1LMNAMAPTRAB9A | |
| SCHEMBL6112679 | 0.80 | KDM4E (0.53) | KDM4ENPC1LMNAMAPTRAB9A | |
| SCHEMBL408881 | 0.80 | KDM4E (0.53) | KDM4ENPC1LMNAMAPTRAB9A | |
| SCHEMBL5316997 | 0.80 | KDM4E (0.50) | KDM4ENPC1LMNAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897866-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| CN-111278821-B | Spiro compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-3704114-B1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220081418-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2022-03-17 | — | — | US | disclosed |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11078198-B2 | Spirocyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3704114-A1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20190127362-A1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| EP-3419969-A1 | HETEROARYL INHIBITORS OF PAD4 | Padlock Therapeutics, Inc. (US) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017147102-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | CORBETT JEFFREY WAYNE | 2009-10-29 | — | — | US | disclosed |
| EP-2097420-A1 | SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Products Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008065508-A1 | SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2007069053-A1 | BENZIMIDAZOLE ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | KDM4E 117/4885NPC1 1597/4885LMNA 3266/4885 |
| US-20190127362-A1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H4, FXR1, NR1H2 | KDM4E 3701/4885NPC1 174/4885LMNA 3362/4885 |
| US-11897866-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | KDM4E 117/4885NPC1 1597/4885LMNA 3266/4885 |
| US-11078198-B2 | Spirocyclic compounds as farnesoid X receptor modulators | NR1H4, FXR1, NR1H2 | KDM4E 3701/4885NPC1 174/4885LMNA 3362/4885 |
| US-20220081418-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | KDM4E 117/4885NPC1 1597/4885LMNA 3266/4885 |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | KDM4E 1062/4885NPC1 715/4885LMNA 2708/4885 |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | KDM4E 117/4885NPC1 1597/4885LMNA 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.